Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald

Arcturus Therapeutics (NASDAQ:ARCT)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Friday,Benzinga reports.

Other research analysts also recently issued research reports about the stock. BTIG Research began coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target for the company. Wells Fargo & Company reduced their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a report on Friday. Finally, HC Wainwright restated a “buy” rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday, February 14th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $61.40.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $14.55 on Friday. The stock has a market capitalization of $394.12 million, a PE ratio of -6.55 and a beta of 2.96. The business has a 50 day simple moving average of $16.95 and a 200-day simple moving average of $18.57. Arcturus Therapeutics has a 12 month low of $14.11 and a 12 month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. On average, equities research analysts anticipate that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Arcturus Therapeutics by 45.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock worth $52,819,000 after purchasing an additional 712,650 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Arcturus Therapeutics during the fourth quarter worth approximately $9,312,000. Schonfeld Strategic Advisors LLC boosted its stake in Arcturus Therapeutics by 129.7% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company’s stock worth $14,409,000 after buying an additional 479,482 shares during the last quarter. J. Goldman & Co LP purchased a new stake in Arcturus Therapeutics in the 4th quarter valued at $5,024,000. Finally, MPM Bioimpact LLC increased its stake in shares of Arcturus Therapeutics by 109.5% in the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company’s stock worth $7,805,000 after acquiring an additional 240,435 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.